Omnicell (OMCL) Misses Q3 EPS by 1c

Omnicell (NASDAQ: OMCL) reported Q3 EPS of $0.40, $0.01 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $176.7 million versus the consensus estimate of $179.75 million.

"Omnicell completed another strong quarter marked by record revenues and market share gains," said Randall Lipps, Omnicell President, CEO and Chairman. "Omnicell's continued growth is the result of successfully broadening our product portfolio, expanding the markets we participate in, and partnering with our customers to address medication management across the full continuum of patient care. The Company is well positioned to take advantage of the great opportunities ahead," Mr. Lipps added.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

You May Also Be Interested In

• First Solar raised at Baird as Section 232 clears path for bookings
• ACCESS Newswire Inc. (ACCS) Misses Q2 EPS by 17c
• Mereo BioPharma (MREO) Reports In-Line Q2 EPS